Why the Next Science share price has surged more than 6% today

The Next Science share price has surged more than 6% following the company's signed distribution agreement in the US.

| More on:

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Next Science Ltd (ASX: NXS) share price is up 6.94% in today's trading session. The price action follows a price sensitive announcement from the medical technology company regarding a distribution agreement in the US.

a woman

What did Next Science announce?

According to the announcement, Next Science has signed a 5-year, distribution deal to distribute its TorrentX Wound Wash product in the US. Under the exclusive deal, Tennessee-based Triad Life Sciences (TLS) has been tasked with promoting, marketing, sales and distribution of TorrentX Wound Wash in the US.

TorrentX Wound Wash is an infection prevention technology from Next Science, used in emergency rooms, hospital treatment rooms and in-home treatment. TorrentX will be paired with a tissue substitute from TLS for chronic wounds and surgical care. A clause in the deal stipulates that TLS must meet performance criteria in order to retain exclusivity.

Once FDA 510(k) clearance is received (expected in Q3 of 2020), TLS will commence exclusive sales of the paired products under the brand name 'TridentX'.

How has Next Science performed in 2019?

Next Science is a medtech company headquartered in Sydney, with a research and development centre in Florida. The company focuses on the development and commercialisation of infection control products and already boasts 4 anti-bacterial FDA-approved products. Next Science's flagship Xbio product is a unique technology that is used to reduce the impact of biofilm-based infections and free-floating bacteria.

The medical technology company listed on the ASX in April this year at an IPO price of $1.00 and quickly hit an all-time high of $4.73 in June. 

The Next Science share price has since pulled back from its all-time highs after the company reported an operating cash loss of US$2 million for the quarter ending 30 September 2019. The company also reported US$927,000 in revenue for the quarter with cash receipts down from $1.2 million from the prior quarter.

Late last week, Next Science received patent coverage for its Xbio Acne Gel and Acne cream from the US Patent office.

The Next Science share price is currently trading at $1.85, valuing the company at around $331 million.

Motley Fool contributor Nikhil Gangaram has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Share Market News

Share Market News

Testing again

Read more »

Share Market News

Aaron Test 2

Read more »

Share Market News

Aaron Test

Read more »

Share Market News

JP Test

Read more »

Share Market News

JP Test

Read more »

Portrait of Discovery Fund portfolio managers Mark Devcich and Chris Bainbridge
Share Market News

Test

Portfolio managers Mark Devcich (left) and Chris Bainbridge. Image source: Discovery Fund test test

Read more »

a man in a hoodie grins slyly as he sits with his hands poised on a keyboard. He is superimposed with a graphic image of a computer screen asking for a password, suggesting he is a hacker.
Share Market News

Another ASX 200 company has been hit with a cyber incident. Here's what we know

Hackers have breached the systems of this ASX 200 company.

Read more »

a woman
Broker Notes

5 ASX 200 shares that inflation can't touch: expert

Regardless of whether you're a bull or a bear, cost pressures are a factor when buying stocks at the moment.

Read more »